Literature DB >> 17827260

Mitochondrial arginase II constrains endothelial NOS-3 activity.

Hyun Kyo Lim1, Hyun Kyoung Lim, Sungwoo Ryoo, Alex Benjo, Karl Shuleri, Victor Miriel, Ezra Baraban, Andre Camara, Kevin Soucy, Daniel Nyhan, Artin Shoukas, Dan E Berkowitz.   

Abstract

Emerging evidence supports the idea that arginase, expressed in the vascular endothelial cells of humans and other species, modulates endothelial nitric oxide (NO) synthase-3 (NOS-3) activity by regulating intracellular L-arginine bioavailability. Arginase II is thought to be expressed in the mitochondria of a variety of nonendothelial cells, whereas arginase I is known to be confined to the cytosol of hepatic and other cells. The isoforms that regulate NOS-3 and their subcellular distribution, however, remain incompletely characterized. We therefore tested the hypothesis that arginase II is confined to the mitochondria and that mitochondrial arginase II reciprocally regulates vascular endothelial NO production. Western blot analysis, immunocytochemistry with MitoTracker, and immunoelectron microscopy confirmed that arginase II is confined predominantly but not exclusively to the mitochondria. Arginase activity was significantly decreased, whereas NO production was significantly increased in the aorta and isolated endothelial cells from arginase II knockout (ArgII(-/-)) mice compared with wild-type (WT) mice. The vasorelaxation response to acetylcholine (ACh) was markedly enhanced and the vasoconstrictor response to phenylephrine (PE) attenuated in ArgII(-/-) in pressurized mouse carotid arteries. Furthermore, inhibition of NOS-3 by N(G)-nitro-L-arginine methyl ester (L-NAME) impaired ACh response and restored the PE response to that observed in WT vessels. Vascular stiffness, as assessed by pulse wave velocity (PWV), was significantly decreased in ArgII(-/-) compared with WT mice. On the other hand, 14 days of oral L-NAME treatment significantly increased PWV in both WT and ArgII(-/-) mice, such that they were not significantly different from one another. These data suggest that arginase II is predominantly confined to the mitochondria and that this mitochondrial arginase II regulates NO production, vascular endothelial function, and vascular stiffness by modulating NOS-3 activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827260     DOI: 10.1152/ajpheart.00700.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  29 in total

1.  Arginase II inhibition prevents nitrate tolerance.

Authors:  S M L Khong; K L Andrews; N N Huynh; K Venardos; A Aprico; D L Michell; M Zarei; K T Moe; G J Dusting; D M Kaye; J P F Chin-Dusting
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids.

Authors:  Vito Porcelli; Giuseppe Fiermonte; Antonella Longo; Ferdinando Palmieri
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

4.  Upregulation of arginase activity contributes to intracellular ROS production induced by high glucose in H9c2 cells.

Authors:  Lu Zhou; Chuan-Bo Sun; Chao Liu; Yue Fan; Hong-Yi Zhu; Xiao-Wei Wu; Liang Hu; Qing-Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Effects of angiotensin type 1 receptor blockade on arginine and ADMA synthesis and metabolic pathways in fawn-hooded hypertensive rats.

Authors:  Gin-Fu Chen; Laszlo Wagner; Jennifer M Sasser; Sergey Zharikov; Natasha C Moningka; Chris Baylis
Journal:  Nephrol Dial Transplant       Date:  2010-05-19       Impact factor: 5.992

6.  Arginase II deletion increases corpora cavernosa relaxation in diabetic mice.

Authors:  Haroldo A Toque; Rita C Tostes; Lin Yao; Zhimin Xu; R Clinton Webb; Ruth B Caldwell; R William Caldwell
Journal:  J Sex Med       Date:  2010-11-03       Impact factor: 3.802

7.  Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans.

Authors:  Lacy A Holowatz; Lakshmi Santhanam; Alanah Webb; Dan E Berkowitz; W Larry Kenney
Journal:  J Physiol       Date:  2011-02-21       Impact factor: 5.182

8.  Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans.

Authors:  Lacy A Holowatz; W Larry Kenney
Journal:  J Physiol       Date:  2011-08-01       Impact factor: 5.182

9.  Arginase-2 mediates renal ischemia-reperfusion injury.

Authors:  Wesley M Raup-Konsavage; Ting Gao; Timothy K Cooper; Sidney M Morris; W Brian Reeves; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-17

10.  Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells.

Authors:  Sergey Zharikov; Karina Krotova; Hanbo Hu; Chris Baylis; Richard J Johnson; Edward R Block; Jawaharlal Patel
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-10       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.